Boehringer and Eli Lilly have started a large-scale trial of their diabetes drug Jardiance in acute heart failure, seeking to get ahead of rivals such as AstraZeneca. The new study - called ...
AstraZeneca's SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback